Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
54.7M
-
Number of holders
-
133
-
Total 13F shares, excl. options
-
65.5M
-
Shares change
-
+2.16M
-
Total reported value, excl. options
-
$744M
-
Value change
-
+$30.2M
-
Number of buys
-
73
-
Number of sells
-
-49
-
Price
-
$11.35
Significant Holders of Stoke Therapeutics, Inc. - Common Stock, $0.0001 par value per share (STOK) as of Q2 2025
152 filings reported holding STOK - Stoke Therapeutics, Inc. - Common Stock, $0.0001 par value per share as of Q2 2025.
Stoke Therapeutics, Inc. - Common Stock, $0.0001 par value per share (STOK) has 133 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 65.5M shares
.
Largest 10 shareholders include FMR LLC (7.41M shares), BlackRock, Inc. (5.92M shares), Lynx1 Capital Management LP (5.4M shares), RTW INVESTMENTS, LP (5.12M shares), BAKER BROS. ADVISORS LP (4.63M shares), Redmile Group, LLC (4.38M shares), MORGAN STANLEY (3.57M shares), Skorpios Trust (3.26M shares), TORONTO DOMINION BANK (3.17M shares), and VANGUARD GROUP INC (2.95M shares).
This table shows the top 133 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.